Trials / Recruiting
RecruitingNCT06059469
PSMA-PET/CT to Assess the Expression of Specific Membrane Antigen (PSMA) in Patients With Progressive Triple-negative Breast Cancer.
PRISMA: A Single-centre, Prospective Phase II Imaging Study Using PSMA-PET/CT to Assess the Expression of Specific Membrane Antigen (PSMA) in Patients With Progressive Triple-negative Breast Cancer.
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Jules Bordet Institute · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a descriptive, prospective, single centre study. This study will assess PSMA expression via the uptake of radiolabelled PSMA-ligand using PET/CT imaging in mTNBC lesions pre-identified on 18F-FDG PET/CT in order to evaluate the feasibility of molecular radionuclide therapy in refractory mTNBC using the Lutetium-177 radiolabelled PSMA.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Ga-PSMA PET/CT | Patient undergo Ga-PSMA PET/CT prior to the start of the new drug treatment |
Timeline
- Start date
- 2022-05-30
- Primary completion
- 2025-06-02
- Completion
- 2025-12-01
- First posted
- 2023-09-28
- Last updated
- 2025-07-18
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT06059469. Inclusion in this directory is not an endorsement.